← Leaderboards
Charles Michael Van Der Horst
University Of North Carolina Chapel Hill
$17,688,631
Attributed
$17,688,631
Total exposure
42
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2005–15$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$22,330,444 · 43
By mechanism
M01$9,506,540 · 27
U01$4,641,813 · 10
P30$3,407,388 · 3
R25$3,349,657 · 1
U2R$1,423,446 · 1
N01$1,600 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Mark J Kutcher$3,795,959
- Carol E Golin$13,302,800
- Joseph B. Hopfinger$2,106,014
- Keith E Muller$5,369,947
- Gail E Henderson$24,141,176
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsHuman Therapy EvaluationAids TherapyDrug Screening /EvaluationAntiaids AgentHuman Immunodeficiency Virus 1Combination ChemotherapyProtease InhibitorAidsResearch PersonnelGrantPharmacokineticsFundingLinkUniversitiesOpportunistic InfectionsMentorsNorth CarolinaFacultyEpidemiologyCareerZidovudine
Grant awards (159)
Fogarty Global Health Fellows Coordinating Center$30,318
R25 · FY2015 · TW · contact PI
Developmental Core$616,269
P30 · FY2014 · AI · contact PI
Fogarty Global Health Fellows Coordinating Center$206,874
R25 · FY2014 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$70,200
R25 · FY2014 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$28,036
R25 · FY2014 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$5,000
R25 · FY2014 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$1,223,480
R25 · FY2013 · TW · contact PI
Developmental Core$269,478
P30 · FY2013 · AI · contact PI
Fogarty Global Health Fellows Coordinating Center$211,451
R25 · FY2013 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$14,040
R25 · FY2013 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$1,053,800
R25 · FY2012 · TW · contact PI
Developmental Core$297,416
P30 · FY2012 · AI · contact PI
South Africa Tuberculosis/AIDS Training$200,000
U2R · FY2012 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$200,000
R25 · FY2012 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$150,000
R25 · FY2012 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$102,458
R25 · FY2012 · TW · contact PI
Fogarty Global Health Fellows Coordinating Center$54,000
R25 · FY2012 · TW · contact PI
Developmental Core$302,367
P30 · FY2011 · AI · contact PI
South Africa Tuberculosis/AIDS Training$214,996
U2R · FY2011 · TW · contact PI
South Africa Tuberculosis/AIDS Training$42,768
U2R · FY2011 · TW · contact PI
DEVELOPMENTAL CORE$384,307
P30 · FY2010 · AI · contact PI
South Africa Tuberculosis/AIDS Training$212,156
U2R · FY2010 · TW · contact PI
DEVELOPMENTAL CORE$293,893
P30 · FY2009 · AI · contact PI
South Africa Tuberculosis/AIDS Training$209,466
U2R · FY2009 · TW · contact PI
DEVELOPMENTAL CORE$315,761
P30 · FY2008 · AI · contact PI
South Africa Tuberculosis/AIDS Training$270,542
U2R · FY2008 · TW · contact PI
CLINICAL TRIAL: PALIFERMIN (FHUKGF) FOR THE TREATMENT OF INADEQUATE CD4 & LUMPHO$13,352
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR THE PRIMARY P$2,427
M01 · FY2008 · RR · contact PI
DEVELOPMENTAL CORE$282,118
P30 · FY2007 · AI · contact PI
South Africa Tuberculosis/AIDS Training$273,518
U2R · FY2007 · TW · contact PI
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR THE PRIMARY PREVENTION OF MAC$25,162
M01 · FY2007 · RR · contact PI
DEVELOPMENTAL CORE$401,777
P30 · FY2006 · AI · contact PI
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR THE PRIMARY PREVENTION OF MAC$19,125
M01 · FY2006 · RR · contact PI
PREVALENCE AND PERSISTENCE OF HUMAN PAPILLOMA VIRUS DNA IN HIV-INFECTED WOMEN$1,006
M01 · FY2006 · RR · contact PI
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR THE PRIMARY PREVENTION OF MAC$10,765
M01 · FY2005 · RR
PREVALENCE AND PERSISTENCE OF HUMAN PAPILLOMA VIRUS DNA IN HIV-INFECTED WOMEN$1,657
M01 · FY2005 · RR
ACTG 362: Efficacy of Azithromycin Prophylaxis for the Primary Prevention of MAC$12,674
M01 · FY2004 · RR
Study of Samples from HIV Subjects Changing or Initiating Potent Therapy$6,338
M01 · FY2004 · RR
ACTG 384: PROTEASE INHIBITORS AND/OR TRANSCRIPTASE INHIBITORS IN INITIAL HIV INF$1,585
M01 · FY2004 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$190,747
M01 · FY2002 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$190,747
M01 · FY2002 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$190,747
M01 · FY2002 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$190,747
M01 · FY2002 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$190,747
M01 · FY2002 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$190,747
M01 · FY2002 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PATIENTS$190,747
M01 · FY2002 · RR
EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC$190,747
M01 · FY2002 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$190,747
M01 · FY2002 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$190,747
M01 · FY2002 · RR
HIV DISEASE RESEARCH AGENDA$0
U01 · FY2002 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$0
U01 · FY2002 · AI
OUTREACH AGENDA$0
U01 · FY2002 · AI
OUTCOMES COMMITTEE AGENDA$0
U01 · FY2002 · AI
WOMEN'S HEALTH AGENDA$0
U01 · FY2002 · AI
PHARMACOLOGY AGENDA$0
U01 · FY2002 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$0
U01 · FY2002 · AI
NEUROLOGY AGENDA$0
U01 · FY2002 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$0
U01 · FY2002 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,391,459
U01 · FY2001 · AI
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PATIENTS$294,555
M01 · FY2001 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$294,555
M01 · FY2001 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$294,555
M01 · FY2001 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$294,555
M01 · FY2001 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$294,555
M01 · FY2001 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$294,555
M01 · FY2001 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$294,555
M01 · FY2001 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$294,555
M01 · FY2001 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$294,555
M01 · FY2001 · RR
EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC$294,555
M01 · FY2001 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$190,747
M01 · FY2001 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$190,747
M01 · FY2001 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PATIENTS$190,747
M01 · FY2001 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$190,747
M01 · FY2001 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$190,747
M01 · FY2001 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$190,747
M01 · FY2001 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$190,747
M01 · FY2001 · RR
EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC$190,747
M01 · FY2001 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$190,747
M01 · FY2001 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$190,747
M01 · FY2001 · RR
OUTCOMES COMMITTEE AGENDA$0
U01 · FY2001 · AI
HIV DISEASE RESEARCH AGENDA$0
U01 · FY2001 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$0
U01 · FY2001 · AI
NEUROLOGY AGENDA$0
U01 · FY2001 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$0
U01 · FY2001 · AI
PHARMACOLOGY AGENDA$0
U01 · FY2001 · AI
WOMEN'S HEALTH AGENDA$0
U01 · FY2001 · AI
OUTREACH AGENDA$0
U01 · FY2001 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$0
U01 · FY2001 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS$2,250,354
U01 · FY2000 · AI
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$294,555
M01 · FY2000 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$294,555
M01 · FY2000 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$294,555
M01 · FY2000 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$294,555
M01 · FY2000 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$294,555
M01 · FY2000 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$294,555
M01 · FY2000 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$294,555
M01 · FY2000 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$294,555
M01 · FY2000 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$294,555
M01 · FY2000 · RR
CORE--DEVELOPMENTAL$244,002
P30 · FY2000 · HD
CLINICAL CENTER FOR VIRAL ACTIVATION TRANSFUSION STUDY$1,600
N01 · FY2000 · HB
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$241
M01 · FY2000 · RR
LOW DOSE INTERLEUKIN 2 IN HIV 1 INFECTED PATIENTS (ACTG248/819)$241
M01 · FY2000 · RR
REPEAT DOSES OF FTC IN HIV 1 PATIENTS$241
M01 · FY2000 · RR
ACTG--267 PHARMACOKINETICS OF THALIDOMIDE IN SUBJECTS WITH HIV-1 INFECTION$241
M01 · FY2000 · RR
SWAB &SCRAPING SPECIMEN COLLECTION FROM HIV PTS$0
M01 · FY2000 · RR
SWAB &SCRAPING SPECIMEN COLLECTION FROM HIV PTS$0
M01 · FY2000 · RR
SWAB &SCRAPING SPECIMEN COLLECTION FROM HIV PTS$0
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN-12 IN HIV INFECTED PTS$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/ NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR$0
M01 · FY2000 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$0
M01 · FY2000 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$0
M01 · FY2000 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$0
M01 · FY2000 · RR
EFZ/ NFV IN COMBINATION W/ FIXED DOSE COMBINATIONS 3TC/ZDV &IDV IN HIV$0
M01 · FY2000 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$0
M01 · FY2000 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$0
M01 · FY2000 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$0
M01 · FY2000 · RR
ACTG 317: EFFECT OF ORAL &INJECTABLE CONTRACEPTIVES &GENDER ON ZVD$0
M01 · FY2000 · RR
THALIDOMIDE FOR RECURRENT APHTHOUS STOMATITIS IN HIV$0
M01 · FY2000 · RR
THALIDOMIDE FOR RECURRENT APHTHOUS STOMATITIS IN HIV$0
M01 · FY2000 · RR
THALIDOMIDE FOR RECURRENT APHTHOUS STOMATITIS IN HIV$0
M01 · FY2000 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PTS$0
M01 · FY2000 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PTS$0
M01 · FY2000 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PTS$0
M01 · FY2000 · RR
INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2 IN HIV PTS$0
M01 · FY2000 · RR
AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC$0
M01 · FY2000 · RR
SAQUINAVIR/RITONAVIR OR NELFINAVIR/DELAVIRDINE/OR ADEFOVIR DIPIVOXILIN IN HIV PTS$0
M01 · FY2000 · RR
SAQUINAVIR/RITONAVIR OR NELFINAVIR/DELAVIRDINE/OR ADEFOVIR DIPIVOXILIN IN HIV PTS$0
M01 · FY2000 · RR
SAQUINAVIR/RITONAVIR OR NELFINAVIR/DELAVIRDINE/OR ADEFOVIR DIPIVOXILIN IN HIV PTS$0
M01 · FY2000 · RR
HIV &CMV &DEVELOPMENT OF CMV END-ORGAN DISEASE$0
M01 · FY2000 · RR
HIV &CMV &DEVELOPMENT OF CMV END-ORGAN DISEASE$0
M01 · FY2000 · RR
HIV &CMV &DEVELOPMENT OF CMV END-ORGAN DISEASE$0
M01 · FY2000 · RR
DISCONTINUING MAINTENANCE THERAPY IN DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX$0
M01 · FY2000 · RR
DISCONTINUING MAINTENANCE THERAPY IN DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX$0
M01 · FY2000 · RR
DISCONTINUING MAINTENANCE THERAPY IN DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX$0
M01 · FY2000 · RR
DISCONTINUING MAINTENANCE THERAPY IN DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX$0
M01 · FY2000 · RR
THE IMMUNOGENICITY OF REMUNE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
THE IMMUNOGENICITY OF REMUNE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
THE IMMUNOGENICITY OF REMUNE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
THE IMMUNOGENICITY OF REMUNE IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
INDINAVIR SULFATE W/ RITONAVIR IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$0
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$0
M01 · FY2000 · RR
VIRAL ACTIVATION TRANSFUSION STUDY (N01-HB-57122)$0
M01 · FY2000 · RR
INDINAVIR SULFATE W/ RITONAVIR IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
INDINAVIR SULFATE W/ RITONAVIR IN HIV INFECTED PATIENTS$0
M01 · FY2000 · RR
EFFECTS OFAMPRENAVIR, ABACAVIR &3TC IN HIV INFECTED PTS$0
M01 · FY2000 · RR
EFFECTS OFAMPRENAVIR, ABACAVIR &3TC IN HIV INFECTED PTS$0
M01 · FY2000 · RR
EFFECTS OFAMPRENAVIR, ABACAVIR &3TC IN HIV INFECTED PTS$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 W/ ACTIVE ANTIRETROVIRAL THERAPY IN HIV-1 PTS$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 W/ ACTIVE ANTIRETROVIRAL THERAPY IN HIV-1 PTS$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 W/ ACTIVE ANTIRETROVIRAL THERAPY IN HIV-1 PTS$0
M01 · FY2000 · RR
SUBCUTANEOUS IL-2 W/ ACTIVE ANTIRETROVIRAL THERAPY IN HIV-1 PTS$0
M01 · FY2000 · RR